HONcode Certified

This website is certified by Health On the Net Foundation. Click to verify.

This site complies with the HONcode standard for trustworthy health information: verify here.

Bloggers

Carl Heneghan

Carl Heneghan

Deputy Director of the CEBM, GP and clinical lecturer at the University of Oxford.

Ami Banerjee

Ami Banerjee

Cardiology trainee and clinical research fellow at the University of Oxford

Carl Heneghan in action

CEBM Workshops Video Sample - Carl Heneghan - Diagnostic Tests

See Carl Heneghan in action in the CEBM's workshop videos.
Click here

Twitter TrustTheEvidence.net

Search the TRIP Database

TRIP Database


Recent comments

rosiglitazone

15th June 2009 09:55am

Some drugs just never go away, but they should   Carl Heneghan

We first criticized this drug in 2006, when in the BMJ we first mooted rosiglitazone in the DREAM trial – which cost $23million - caused a significant increase in heart failure, despite the population being at low risk of such a problem. The drug showed no clear benefit at 3 years on clinical outcomes and the rate of all cardiovascular events tended to be higher in the treatment group.

Read full article


Syndicate content